Item 9 Labs Corp. (INLB) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.15: the stock has moved about 85% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerItem 9 Labs Corp. (INLB) trades at $0.0001. Item 9 Labs Corp. is a vertically integrated cannabis operator and dispensary franchisor in the United States. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for INLB: INLB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Item 9 Labs Corp. (INLB) Healthcare & Pipeline Overview
Item 9 Labs Corp. operates as a vertically integrated cannabis company, producing and distributing cannabis products through its dispensaries and franchised Unity Rd locations. Focused on the Arizona market, the company navigates the evolving regulatory landscape of the specialty and generic drug manufacturing sector.
What Is the Investment Thesis for INLB?
Item 9 Labs Corp. presents a unique investment opportunity within the cannabis sector due to its vertically integrated business model and dispensary franchising strategy. The company's focus on the Arizona market, combined with its Unity Rd franchise network, positions it for growth as the cannabis industry matures. However, investors may want to evaluate the risks associated with operating in a highly regulated and competitive market. With a negative P/E ratio and a negative profit margin of -143.1%, the company's profitability is a concern. Key growth catalysts include expansion of the dispensary network and increased brand recognition. The company's gross margin of 33.6% indicates potential for improved profitability with scale. The company's beta of 0.15 suggests low volatility relative to the market.
Based on FMP financials and quantitative analysis
INLB Key Highlights
Vertically integrated operations provide control over the entire cannabis value chain, from cultivation to retail.
- Franchise model through Unity Rd offers a scalable approach to expanding dispensary network.
- Focus on the Arizona market allows for targeted marketing and distribution strategies.
- Gross margin of 33.6% indicates potential for profitability improvements.
- Negative profit margin of -143.1% highlights the need for improved cost management and revenue growth.
Who Are INLB's Competitors?
INLB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AKAN Akanda Corp. | $1.91 | -3.54% | — | |
| APUS Apimeds Pharmaceuticals US, Inc. | $4.59 | +42.55% | $7.59M | — |
| BFRI Biofrontera Inc. | $0.89 | -12.23% | $11.4M | — |
| COSM COSM | $0.35 | -9.03% | $20.7M | — |
| QNTM Quantum BioPharma Ltd. | $3.27 | -4.94% | $20.9M | — |
| AYTU Aytu BioPharma, Inc. | $2.04 | -1.45% | $21.9M | — |
| TXMD TherapeuticsMD, Inc. | $2.01 | -1.95% | $24.0M | — |
| CPHI CPHI | $0.65 | -0.61% | $27.0M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are INLB's Key Strengths?
Vertically integrated operations
- Franchise model for expansion
- Established presence in Arizona
- Diverse product offerings
What Are INLB's Weaknesses?
Negative profitability
- Limited geographic diversification
- Reliance on a single state market (Arizona)
- Small market capitalization
What Are the Key Risks for INLB?
Financial-distress signal — its Altman Z-Score of -2.03 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-42.1%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
- Regulatory uncertainty and changes in cannabis laws.
- Intense competition from other cannabis companies.
- Fluctuations in cannabis prices and supply.
- Negative profitability and the need for improved cost management.
- Limited access to capital and financing challenges.
What Are INLB's Competitive Advantages?
- Vertically integrated operations provide cost advantages and quality control.
- Unity Rd franchise network offers a scalable expansion model.
- Established presence in the Arizona cannabis market.
What Does INLB Do?
Item 9 Labs Corp., headquartered in Phoenix, Arizona, is a vertically integrated cannabis operator and dispensary franchisor. The company cultivates, processes, and retails cannabis and cannabis-related products. Its operations span various product categories, including flower, concentrates, distillates, and hardware. Item 9 Labs distributes its products through its own licensed dispensaries and through franchised locations operating under the Unity Rd brand. The company focuses primarily on the Arizona market, catering to both medical and adult-use cannabis consumers. Its business model integrates cultivation, manufacturing, distribution, and retail sales, allowing for greater control over product quality and supply chain efficiency. Item 9 Labs also seeks to expand its footprint through franchising, offering entrepreneurs the opportunity to operate cannabis dispensaries under a recognized brand. The company's vertically integrated approach aims to capture a larger share of the cannabis value chain, from seed to sale. The company's strategy involves expanding its dispensary network and product offerings to meet the growing demand for cannabis products in Arizona and beyond.
What Products and Services Does INLB Offer?
- Cultivates cannabis plants.
- Processes cannabis into various products like flower, concentrates, and distillates.
- Manufactures cannabis-related hardware.
- Operates licensed cannabis dispensaries in Arizona.
- Sells medical and adult-use cannabis products.
- Franchises cannabis dispensaries under the Unity Rd brand.
How Does INLB Make Money?
- Vertically integrated operations from cultivation to retail sales.
- Generates revenue through direct sales at company-owned dispensaries.
- Earns franchise fees and royalties from Unity Rd franchisees.
What Industry Does INLB Operate In?
Item 9 Labs Corp. operates within the rapidly evolving cannabis industry, which is characterized by increasing legalization and growing consumer demand. The market is highly competitive, with numerous companies vying for market share. The company's vertically integrated model and franchise strategy differentiate it from some competitors, but it also faces challenges from larger, well-capitalized players. The industry is subject to significant regulatory uncertainty, which can impact operations and profitability. The company's focus on the Arizona market provides a degree of geographic concentration, but also exposes it to state-specific regulatory risks.
Who Are INLB's Key Customers?
- Medical cannabis patients in Arizona.
- Adult-use cannabis consumers in Arizona.
- Entrepreneurs seeking to operate cannabis dispensaries through the Unity Rd franchise program.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Insider Activity
12 transactions · 0 purchases, 0 sales, 12 other transactions · 5 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Key Financial Metrics
Return on equity for Item 9 Labs Corp. stands at -42.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -28.1%, showing how much profit it generates from its asset base. A current ratio of 0.09 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Item 9 Labs Corp.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.03 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Item 9 Labs Corp. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 86.7% below estimates on average.
Company Profile
Item 9 Labs Corp. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Phoenix, US. The company is led by CEO Jeffrey I. Rassas. INLB has traded publicly since 2012.
INLB Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
INLB Latest News
No recent news available for INLB.
INLB Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for INLB.
Price Targets
Wall Street price target analysis for INLB.
INLB MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for INLB; grades run from A+ (80-100) to F (below 30).
Leadership: Jeffrey I. Rassas
CEO
Jeffrey I. Rassas serves as the CEO of Item 9 Labs Corp. He has been instrumental in guiding Item 9 Labs' growth strategy, focusing on vertical integration and franchise expansion. His leadership is focused on navigating the complex regulatory landscape of the cannabis industry and driving revenue growth.
Track Record: Under Jeffrey I. Rassas's leadership, Item 9 Labs Corp. has expanded its dispensary network and franchise operations. He has overseen the development of new cannabis products and the implementation of strategic partnerships. His focus has been on building a sustainable and scalable business model in the rapidly evolving cannabis market. However, the company's path to profitability remains a key challenge.
INLB OTC Market Information
OTC Other, also known as the Grey Market, represents the lowest tier of the OTC market. Companies in this tier often do not meet minimum financial standards and may not provide regular financial disclosures. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to exchanges like the NYSE or NASDAQ. These companies may be defunct, experiencing financial distress, or unwilling to adhere to higher reporting standards. Investors should exercise extreme caution and conduct thorough due diligence before considering an investment in an OTC Other company.
- OTC Tier: OTC Other
- Limited financial disclosure
- Low trading volume and liquidity
- Potential for price manipulation
- Higher risk of fraud or mismanagement
- Lack of regulatory oversight
- Verify the company's legal status and registration.
- Obtain and review any available financial statements.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Check for any legal or regulatory issues.
- Understand the risks associated with the OTC Other tier.
- Consult with a qualified financial advisor.
- Company's operational status (active vs. defunct)
- Existence of a physical headquarters and operational facilities
- Presence of a management team and employees
- Any available news or press releases about the company
- Information from third-party sources (if available)
Item 9 Labs Corp. Healthcare Stock: Key Questions Answered
What do analysts say about INLB stock?
As of March 16, 2026, there is no readily available analyst coverage or consensus on Item 9 Labs Corp. (INLB) stock, likely due to its OTC listing and small market capitalization. Investors should conduct their own thorough research and due diligence before considering an investment in INLB.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Financial data is limited due to the company's OTC listing and disclosure status.
- Analyst coverage is not available for this stock.